Product description

Embozene Tandem^® microspheres are designed for drug loading and elution of a local, controlled, sustained drug dose after embolization. They are available in three highly calibrated microsphere sizes (40, 75 and 100 μm) in volumes of 2 and 3 ml of product, and presented in prefilled syringes. Each microsphere, meticulously crafted with ≥95% of the microspheres being within the specified size range ⁽¹⁾, guarantees accurate targeting of the specific vasculature.

Size matters: Small and Precise Microspheres Prolonging Lives in Liver Care

Embozene Tandem^® microspheres redefine precision with sizes down to 40 μm, ensuring targeted delivery of cytostatic drugs to tumor-feeding arteries.

The smaller particle sizes (40 or 75 μm) contribute to better intratumoral distribution ⁽⁴⁾, allowing physicians precise control in delivering chemotherapy directly to tumor-feeding arteries, when performing selective TACE (Transarterial chemoembolization) ^{(5, 15)}. This enhances the concentration of drugs within the tumor leading to high therapy response and disease control rates, while minimizing the risk of local complications, providing a balance of efficacy and safety ^{(6-12, 24)}.

In an examination of liver explants in humans, it was found that just 42% of blocked vessels resided within the tumor when employing 100–300 μm DEBs (drug-eluting beads) ⁽¹³⁾. This underlines the importance of smaller and precisely calibrated DEBs, which allow a more distal embolization in the tumoral arterial network.

The 40 μm Embozene Tandem^® beads allow deep and large volume implantation into the tumor. Histological examinations show the presence of doxorubicin-loaded beads within the interstitium of the tumor, the deepest level achievable ⁽¹⁵⁾.

DEB (white arrows), in large numbers, within the interstitium, with adjacent capillaries observed. (CD34 immunostaining of capillaries; original magnification, x20) ⁽¹⁵⁾

Patient-Centric Precision: Strength in Numbers

Due to their tight and uniform size distributions, more microspheres occupy the same volume as compared with a wider size range. For example, a sphere with a diameter of 300 μm occupies 27-times the volume of one 100-μm sphere, thus enabling more 100-μm spheres to occupy the same volume as one 300-μm sphere ⁽¹³⁾.

Embozene Tandem^® Microspheres excel in precise calibration, enabling the delivery of a greater number of small microspheres (≤100 μm) in the same volume. This advantage promotes deeper penetration, higher density, and more predictable coverage within the tumor, enhancing drug exposure and distribution for optimal therapeutic outcomes ^{(13, 15, 16)}.

Empowering Patient Outcomes with Flexibility

The distinctive solutions, featuring single unit syringes in 2 ml or 3 ml options, set a new standard for flexibility in microsphere counts, while distinguishing it as the sole 3 ml drug-eluting microsphere product on the market.

Tailored Treatment Approach

The ability to load Embozene Tandem^® with various chemotherapeutic agents allows a personalized treatment strategy, addressing each patient’s unique condition and characteristics.

Rapid and Reliable Drug Loading

Embozene Tandem^® microspheres achieve over 99% doxorubicin loading within just 1 hour and 30 minutes for the loading of irinotecan, ensuring swift and dependable drug incorporation ⁽¹³⁾.

(a) entire duration and (b) reduced time range to illustrate the differences in loading ⁽²⁾.

Microsphere Stability and Consistency

Embozene Tandem^® microspheres maintain their distinct shapes and remain separate and spherical, before and after loading with doxorubicin, ensuring stability and consistency ⁽²⁾.

Photomicrographs of doxorubicin-loaded LifePearl (a), DC Bead (b), Tandem (c), and HepaSphere (d) microspheres. Inset images in the lower left corners are photomicrographs of unloaded microspheres. (Scale bars: 200 µm.) ⁽²⁾

The average diameters of LifePearl, DC Bead, and Tandem microspheres were reduced after loading by 24%, 20%, and 9%, respectively ⁽²⁾.

Diameter distribution histograms of doxorubicin-loaded DC Bead (blue), HepaSphere (orange), LifePearl (green), and Embozene Tandem^® (red) microspheres ⁽²⁾.

Optimizing Treatment Strategies: Tandem^® Microspheres Lead with Enhanced Doxorubicin Release Capacity
Designed to load up to 50 mg/ml of doxorubicin, Embozene Tandem^® Microspheres set a new standard in the market, offering healthcare professionals the option to release more doxorubicin, if needed and tolerated by the patient, for improved tumor necrosis. As the exclusive provider of a 3 ml drug-eluting microsphere product, it empowers healthcare professionals to deliver up to 150 mg maximum dose per patient with unparalleled precision and efficacy.

The versatile drug loading possibilities of the Embozene Tandem^® microspheres empower physicians to tailor the treatment by choosing and loading the beads with the most suitable chemotherapeutic agent and dose. This personalized approach addresses the unique needs of each patient for a more effective outcome.

Embozene Tandem^® at the forefront of TACE treatment

Enhanced Pharmacokinetics for patient comfort

The hydrogel matrix of Embozene Tandem® ensures efficient intratumoral concentrations and a sustained drug release, resulting in improved pharmacokinetic profiles ⁽¹⁹⁾. This translates to minimized systemic side effects, enhancing patient comfort and compliance throughout the treatment process and a smoother recovery process with reduced post-procedural discomfort, making it the ideal choice for advancing patient care ^{(12, 13)}.

The Embozene Tandem^® (Oncozene in US) microspheres offer a dual advantage by necessitating a significantly lower doxorubicin dose in comparison to alternative products, thus potentially minimizing drug-related adverse effects ⁽²⁰⁾, while demonstrating comparable or superior short-term radiographic tumor response and survival rates, affirming its efficacy and safety. Furthermore, the lower doxorubicin doses suggest a potential cardioprotective benefit, particularly relevant for patients undergoing multiple TACE procedures ⁽¹⁹⁾.

Extended Time in Suspension

Embozene Tandem^® microspheres exhibit prolonged time in suspension after loading with doxorubicin, facilitating smoother embolization procedures without frequent interruptions ⁽²⁾.

Discover the future of Irinotecan therapy: The benefits of Embozene Tandem^® Microspheres

In comparison with alternative products, Embozene Tandem^® microspheres exhibit delayed irinotecan elution, with approximately 70% elution at 6 hours. This offers a unique advantage for patients by minimizing systemic side effects throughout the treatment process and minimizing post-procedural discomfort, while resulting in equivalent treatment efficacy ^{(13, 21-23)}.

Additionally, after loading with irinotecan, the average diameter was unchanged for Embozene Tandem^® microspheres, while the average diameter of alternative products was reduced by 9% and 18% respectively ⁽³⁾.

Selected products available directly from our warehouse in Zuchwil – additional variants on request.
All items listed below are in stock at our Zuchwil warehouse and ready for immediate dispatch.

Looking for a different size or variant? No problem – we’ll gladly check availability of other options upon request and provide you with individual delivery information.

*Orders received by 4:00 p.m. on business days are dispatched the same day via A-Post.
Please note: on the day before a public holiday, we can accept orders until 2:00 p.m.

to the PDFs: